Drug Profile
Tosatoxumab - Aridis Pharmaceuticals
Alternative Names: Anti-S.aureus-mAb; Anti-S.aureus-monoclonal-antibody; Anti-Staphylococcus-aureus-mAb; Anti-Staphylococcus-aureus-monoclonal-antibody; AR 301 (anti-Sa mAb) - Aridis Pharmaceuticals; AR-301; KBSA-301; SalvecinLatest Information Update: 20 Nov 2023
Price :
$50
*
At a glance
- Originator Kenta Biotech
- Developer Aridis Pharmaceuticals; Kenta Biotech
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Bacterial toxin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Ventilator associated pneumonia
- Discontinued Sepsis